The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- SPORTS THERAPY – A GREAT WAY TO MAINTAIN A HEALTHY BODY
- How researchers are mapping the future of quantum computing, using the tech of today – GeekWire
- Colorado makes a bid for quantum computing hardware plant that would bring more than 700 jobs – The Denver Post
- The Worldwide Quantum Computing Industry is Expected to Reach $1.7 Billion by 2026 – PRNewswire
- bp Joins the IBM Quantum Network to Advance Use of Quantum Computing in Energy – HPCwire
- dr ortiz greys anatomy
- jaw numbnesd after a tooth extraction
- greys anatomy cast dr ortiz
- mother daughter interna on greys amatomy
- dr ortiz on greys anatomy
- who plays dr orttiz on grays anatomy
- iplness that killed jackson averys baby
- innie vs outie vagian
- mama ortiz on greys anatomy
- what happens when jackson find out about the baby after divorce
|Search Immortality Topics:|
Category Archives: Anti-Aging Medicine
Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing – BioSpace
SHANGHAI, Nov. 27, 2020 /PRNewswire/ -- Eluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to the discovery and development of first-in-class and/or best-in-class therapies, today announced the completion of a $50 million (USD) Series A Financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital. The Eluminex headquarters and research and development center are located in Suzhou Industrial Park; the business center is based in Shanghai, and future plans include establishing a global clinical and registration center in the San Francisco Bay Area.
"We greatly appreciate the profound level of support and trust from three global investors,"said Jinzhong Zhang, PhD, Co-Founder, Chairman, and Chief Executive Officer. "With these proceeds, our goal is to build an innovative pipeline addressing critical unmet medical needs in vision-threatening diseases for patients worldwide. Additionally, we are pleased to have three world-renowned professors of ophthalmology as members of our Scientific Advisory Board: Quan Dong Nguyen, MD, MSc (Stanford University), Zuguo Liu, MD, PhD (Xiamen University), and Xiaodong Sun, MD, PhD (Shanghai Jiao Tong University). We are grateful for their significant contributions in helping us develop our pipeline programs."
The company also announced that Charles Semba, MD, has joined Eluminex as Chief Medical Officer (CMO). Dr. Semba is an internationally recognized leader in ophthalmic drug development. He has served as CMO in three prior ophthalmic companies: SARcode Bioscience (acquired by Shire/Takeda), ForSight VISION5 (acquired by Allergan), and Graybug Vision (NASDAQ: GRAY). He has held senior leadership roles as Vice President Ophthalmic Medicine at Shire/Takeda and Ophthalmology Group Head at Genentech. Dr. Semba led the clinical development of ranibizumab (LUCENTIS), the first global blockbuster anti-VEGF agent to reverse blindness in wet age-related macular degeneration and lifitegrast (XIIDRA), the first novel agent for the treatment of both signs and symptoms of dry eye disease; XIIDRA was acquired by Novartis for over $5 billion (USD).
Regarding the success of this financing, all parties have expressed their confidence and expectations for the new company. "Closing Series A financing is indeed a major milestone. The leadership at Eluminex should be congratulated for this impressive achievement amidst current global events," commented Dr. Nguyen, Professor of Ophthalmology at the Byers Eye Institute, Stanford University. "Such financial success and security demonstrate the trusts that the company has earned from the investment community in Eluminex's research and development therapeutic plans to preserve and enhance vision for patients with devastating ocular diseases worldwide."
"Driven by an aging population and overuse of eyes in various ages, the ophthalmic market is seeing huge unmet needs for new products. The team's solid track record and rich experience in ophthalmic drug development enables the company to develop innovative therapies not only for China but also for the global market. We are thrilled and honored to join hands with this seasoned team and partner with the reputable investors from the very beginning," said Stephen Lin, Partner at Lilly Asia Ventures.
"The founding team of Eluminex Biosciences has rich experience in drug development and innovation with great potential in the future. Hillhouse will help Eluminex continue to innovate, research and develop leading ophthalmic disease treatment drugs, meeting the needs of a large number of patients, and continue to create social well-being," said Michael Yi, Partner and Co-Chief Investment Officer of Hillhouse Capital Group.
"Quan Capital is committed to foster innovation and bring new solutions to patients with great unmet needs. We are pleased to co-lead the Series A round of Eluminex and are truly impressed by the stellar management team," said Marietta Wu, Managing Director of Quan Capital. "We believe this team of seasoned industry veterans both globally and in China will build a leader in ophthalmology with accelerated development of novel therapeutics. Quan looks forward to working closely with the team and contributing our local resources and global networks."
About Eluminex Biosciences
Eluminex was established in February 2020 with the commitment to leading the development of novel therapeutics for the benefit of patients with vision-threatening eye diseases worldwide. Co-Founders, Dr. Jinzhong Zhang and Dr. Zhenze John Hu, have assembled a top tier management team with significant ophthalmic drug development experience, aiming to build a robust and sustainable innovative ophthalmic pipeline to tackle the unmet clinical needs. For detailed information contact Zhenze John Hu at email@example.com
About Lilly Ventures Asia
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Menlo Park. LAV's vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that can treat diseases and improve human health.For more information, visit http://www.lillyasiaventures.com.
About GL Ventures
GL Ventures focuses on early-stage innovative companies in healthcare, software services, consumer Internet, emerging consumer brands and services. The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time. GL Ventures is the early stage affiliate of Hillhouse Capital, and we have been investing with innovators across the world since 2005. We were one of the earliest investors into some of the largest global companies today, including BeiGene, Zoom, Meituan, JD, Woowa Brothers and many more.
About Quan Capital
Quan Capital (Quan) is a life sciences venture capital firm with strong China expertise and global capabilities. Quan discovers, incubates, and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. With offices in Shanghai, Palo Alto and Boston, Quan's investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and leverage their broad network worldwide to help maximize the company's value across geographies and development stages.For more information, visit http://www.quancapital.com.
SOURCE Eluminex Biosciences
In an overwhelmingly anxious year, your phone might ironically be your best friend when it comes to relaxation. Meditation apps like Calm and Headspace have gained momentum in the past few years and Covid-19 has lead to a surge in downloads. These apps have been designed to guide users in meditation, helping them deal with anxiety, relieve stress and fall asleep.
According to Sensor Tower, the 10 largest English language meditation apps saw a combined 2 million more downloads during April 2020 compared with January. Globally, the most downloaded app was Calm with 3.9 million downloads in April 2020. Though we are mostly advised to put our phones away well before bed, in this case, we might be granted a reprieve. Although it is obviously betternotto sleep with your iPhone by your side, meditating without guidance when youre not very good at it is ill-advised.
Psychoanalyst Claudia Luiz told Shape magazine that during the night, many people lack sufficient defenses to guard against unbearable thoughts andfeelings. This leads to a chronic, low-grade state of fight or flight. As a result of this, hormones cortisol and adrenaline are excreted and disrupt sleep. Every single year, more than 50 million people in the US are diagnosed with sleep disorders. If apps can help us relax and get a good nights sleep, why not? Luiz also mentions that everyone will need something slightly different to begin their relaxation journey. If sleep stories arent working, try music or a sleep podcast but dont beat yourself up.
Sleep apps use everything from colors and images to hypnotic techniques, guided meditations, and white noise to aid relaxation. The American Sleep Association (ASA) analyzed 35 top sleep apps. All the 35 sleep apps analyzed did allow for users to meet their goals in terms of getting to sleep. They did not however have any substantial impact on severely sleep-deprived individuals. Furthermore, very few of these apps provided users with information about the risks of sleep deprivation. These risks include diabetes, obesity, depression, and high blood pressure.
Additionally, the ASA says that sleep apps can also help retrain your brain and can be useful in cognitive behavioral therapy. Whilst in-person counseling for insomnia is ideal, it is often expensive to visit a therapist. Apps that use sleep hygiene and cognitive behavior therapy to improve sleep behaviors are best.
In a randomized control trial which was published in the journalCurrent Sleep Medicine Reports,a group of people with mild insomnia used a phone app to provide cognitive behavioral therapy for seven weeks. The results indicated that the group which made use of the app had a marked decrease in insomnia. This was still in place three months later during a follow-up evaluation.
Below is a quick overview of the global top three sleep apps. It is vital, before committing to a specific app, that you explore each one thoroughly. You should make sure that youre choosing the correct one for you. Most of these apps come with a free trial. This means you can make sure that they suit you before committing.
Calm describes itself as being on a mission to make the world happier and healthier. Globally, Calm is the number one app for sleep, meditation, and relaxation. It has over 50 million downloads and over 700,000 5-star reviews. Calm also has several other features which include videos on mindful movement and an extensive range of music. Calm also features sleep stories read by celebrities which include the likes of Kate Winslet and Harry Styles.
The app is admittedly rather pricey at **$69.99 for an annual subscription.
Download here: https://www.calm.com
Headspace was started by Andy Puddicombe who became a Buddhist monk in his early twenties. After building his meditation know-how for 10 years and completing his monastic commitment, Andy returned to the UK. He had a single goal in mind teaching meditation and mindfulness to as many people as possible. After first launching as an events company in 2010, Headspace morphed into an online meditation platform. According to the website, the Headspace mission is to improve the health and happiness of the world. Headspace specializes in teaching the basics of meditation. It also equips users with tools that they can make use of in real-world situations.
There is a free basics course. However, a subscription will set you back **$69.99 per year, exactly the same as Calm. There is also special pricing available for students and family plans.
Download here: https://www.headspace.com
Meditopia describes its mission as being to help people all over the world discover happiness within themselves and develop the mental resilience to apply to their daily lives. The app was first developed in 2017. The developers noticed that peoples minds were not in the present moment. Meditopia is described as a sort of utopia where everyone works to stay in the present moment. The meditation app was designed with mindfulness instructors, yoga teachers, and emotional healers. Its aim is to analyze the root causes of emotions like stress, anxiety, anger, compassion, and gratitude.
There is a free premium trial that lasts for a week. Once the trial ends, the cost is either $9.99 per month or **$59.99 for the annual plan.
Download here: https://meditopia.com/en/
*Personally, Headspace and Calm have worked the best for me. That said, I also often make use of sleep playlists on Spotify and Audible books.
**All pricing is accurate as of publication date
American Sleep Association. How to Retrain and Reclaim Your Sleep Using a Sleep App. [Online] Available at: https://www.sleepassociation.org/sleep-treatments/sleep-apps/how-to-retrain-and-reclaim-your-sleep-using-a-sleep-app/.
Calm. 2020. Calm App. [Online] Available at: https://www.calm.com
Calm. 2020. Calm Sleep Stories. [Online] Available at: https://app.www.calm.com/sleep?coupon=freetrial.
Headspace. 2020. Headspace App. [Online] Available at: https://www.headspace.com
Headspace. 2020. Headspace App About Us. [Online] Available at: https://www.headspace.com/about-us
Journal of Clinical Sleep Medicine. 2018. Consumer Sleep Technology: An American Academy of Sleep Medicine Position Statement. [Online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940440/
Meditopia. 2020. Meditopia App. [Online] Available at: https://meditopia.com/en/
Perez, S. 2020. Meditation and mindfulness apps continue their surge amid pandemic. [Online] Available at: https://techcrunch.com/2020/05/28/meditation-and-mindfulness-apps-continue-their-surge-amid-pandemic/.
Sensor Tower. 2020. Downloads of Top English-Language Mental Wellness Apps Surged by 2 Million in April Amid COVID-19 Pandemic. [Online] Available at: https://sensortower.com/blog/top-mental-wellness-apps-april-2020-downloads.
Trice, E. 2020. These Celebrity Meditations and Bedtime Stories Will Lull You to Sleep In No Time. [Online] Available at: https://www.shape.com/lifestyle/mind-and-body/celebrity-meditations-bedtime-stories
Worldwide Anti-Aging Market to 2030 – Industry Analysis and Growth Forecast – ResearchAndMarkets.com – Business Wire
DUBLIN--(BUSINESS WIRE)--The "Anti-Aging Market Research Report: By Product, Treatment, Demography - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The major driving factors for the anti-aging market are the rising number of awareness-raising seminars and conferences, surging geriatric population, increasing disposable income, technological advancements, expanding medical tourism sector, and escalating cosmetic surgery volume.
These factors will lead to an increase in the industry revenue from $191.5 billion in 2019 to $421.4 billion in 2030, at an 8.1% CAGR during 2020-2030 (forecast period). Products used to diminish the signs of aging are easily available at physical stores and online portals.
A key factor aiding the anti-aging market advance is the rising number of seminars and conferences being organized to make plastic surgeons, students, and the general public about the advanced anti-aging treatments. For instance, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) hosted by EuroMediCom (Informa Group) in April 2019 in Monte Carlo, Monaco, included five knowledge sharing and discussion sessions on anti-aging and aesthetics. Formerly, the Aesthetic & Anti-Aging Medicine World Congress 13th Edition was hosted in Thailand in September 2018 by the American Academy of Anti-Aging Medicine (A4M).
Another major reason the demand for anti-aging treatments and products is increasing is the booming geriatric population. The United Nations says that the number of people in the age group of 65 and above will surge from 703 million in 2019 to 1.5 billion by 2050. With age, people experience stem cell and fibrous tissue loss, which leads to dryness, wrinkles, sagging, and pigmentary alteration. Therefore, in order to continue looking young and attractive, the geriatric population regularly uses anti-aging remedies, which tighten and revitalize the skin, in addition to making people look young.
North America is the dominant region in the anti-aging market currently, owing to the rising plastic surgery volume and geriatric population. The UN expects the number of elderly people on the continent to increase to 96.2 million by 2050 from 59.9 million in 2019. This, coupled with the growing volume of plastic surgeries, is expected to result in a massive surge in the demand for various therapies and products that help people look young and aesthetically appealing.
For more information about this report visit https://www.researchandmarkets.com/r/rpts2n
About Zhejiang University
Located in the historical and picturesque city of Hangzhou, Zhejiang University is a prestigious institution of higher education with a long history. Qiushi Academy, the predecessor of Zhejiang University, was founded in 1897 and was one of the earliest modern academies of higher learning established in China.
Zhejiang University focuses on assiduous study and research, and science and technological innovation. It has launched a number of international high-end academic platforms and gathered masters, scholars and high-level research teams in various disciplines. In recent years, Zhejiang University maintains a leading position in China in output indicators including publications, patents and etc., and has made abundant important achievements in science, technology, humanities and social sciences. Zhejiang University always takes initiative in catering for national and regional needs, and exerts itself to become an influential high-level source of innovation and a pool of talents.
About International School of Medicine
International School of Medicine, Zhejiang University (hereinafter referred to as the School, ZJU) is a higher medical education institute jointly supported by Zhejiang University and Yiwu government, located in the energetic city Yiwu. Underpinned by R&D driven force of International Research Institutes of Health Medicine, ZJU (the Institute), clinical resources of the 4th Affiliated Hospital, ZJU School of Medicine (ZJU4H) and medical education of International School of Medicine, the 3 in 1 institution, is creating a stimulating, world-class hub for medical education, research and clinical health care with the commitment in empowering future physician scientists, biomedical pioneers and medical leaders to succeed in medical challenges worldwide. It is dedicated in working across disciplines to expand the frontiers of scientific understanding, while converting the most promising breakthroughs into tangible health, to enlarge the scope of medical education and training the future medical leaders and pioneers, to achieve a shared development in future medicine, as well as to advance health and to build a shared future for mankind locally, regionally, nationally and globally.
International School of Medicine, ZJU invites talents in all branches of cutting-edge science and technology around the world. Areas of interest include, but are not limited to, Global Health, Oncology, Reproductive Medicine, Regenerative Medicine, Anti-Aging Medicine General Practice and Digital Medicine. Global talents are welcomed to join a vibrant scientific environment aiming at pressing medical challenges with core technologies in critical areas and conducting interdisciplinary research to address high-priority projects in future medicine. Please come and join us for a better shared future.
HIGHLIGHTS OF THE SCHOOL:
I. POSITION AND REQUIREMENT
Candidates should be an internationally active academic member with globally-recognized contributions. Qualified candidate will be appointed as Qiushi Chair Professors of ZJU.
II.WORKING AND LIVING CONDITIONS
International School of Medicine, ZJU upholds the Universitys tradition of valuing our faculty and are committed to promoting their career development. We continue to optimize the campus academic environment, implement support policies, and offer internationally competitive work and living facilities.
III. REQUIRED DOCUMENTS FOR APPLICATION
Please send the following application documents in PDF format with NAME+POSITION firstname.lastname@example.org
Should you have question please feel free to contact us. Application will be reviewed upon receipt.
Mr. LOU +86-0579-89935020Ms. WANG +86-0571-88208183
Address: No.1575 North Chouzhou Road, Yiwu City, Zhejiang Province, China
COVID-19 Coronavirus molecule, March 24, 2020.
CDC | API | Gamma-Rapho via Getty Images
A team of CRISPR scientists at the New York Genome Center, New York University and Icahn School of Medicine at Mount Sinai say they have identified the genes that can protect human cells against Covid-19, a disease that has infected over 40 million and led to 1 million deaths worldwide. The discovery comes after an eight-month screen of all 20,000 genes in the human genome led by Dr. Neville Sanjana at the New York Genome Center. Leading virologist at Mount Sinai, Dr. Benjamin tenOever, developed a series of human lung cell models for the coronavirus screening to better understand immune responses to the disease and co-authored the study.
Their study, published online last month by Cell, will appear in the scientific peer-reviewed journal's Jan. 7 print issue.
The goal was two-fold: to identify the genes that make human cells more resistant to SARS-CoV-2 virus; and test existing drugs on the market that may help stop the spread of the disease.
The breakthrough comes at a time when drug makers such as Pfizer, Oxford-AstraZeneca and Moderna are fast-forwarding vaccine and therapeutics to treat Covid-19. On Friday, Pfizer and BioNTech requested emergency authorization from the FDA for their Covid vaccine that contains genetic material called messenger RNA, which scientists expect provokes the immune system to fight the virus.
In order to better understand the complex relationships between host and virus genetic dependencies, the team used a broad range of analytical and experimental methods to validate their results. This integrative approach included genome editing, single-cell sequencing, confocal imaging and computational analyses of gene expression and proteomic datasets.
After intensive research the scientists and doctors claim they have found 30 genes that block the virus from infecting human cells including RAB7A, a gene that seems to regulate the ACE-2 receptor that the virus binds to and uses to enter the cell. The spike protein's first contact with a human cell is through ACE-2 receptor.
"Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus," said Dr. tenOever. "It also revealed the virus needs a toolbox of components to infect human cells. Everything must be in alignment for the virus to enter human cells."
The team discovered that the top-ranked genes those whose loss reduces viral infection substantially clustered into a handful of protein complexes, including vacuolar ATPases, Retromer, Commander, Arp2/3, and PI3K. Many of these protein complexes are involved in trafficking proteins to and from the cell membrane.
"We were very pleased to see multiple genes within the same family as top-ranked hits in our genome-wide screen. This gave us a high degree of confidence that these protein families were crucial to the virus lifecycle, either for getting into human cells or successful viral replication," said Dr. Zharko Daniloski, a postdoctoral fellow in the Sanjana Lab and co-first author of the study.
Using proteomic data, they found that several of the top-ranked host genes directly interact with the virus's own proteins, highlighting their central role in the viral lifecycle. The team also analyzed common host genes required for other viral pathogens, such as Zika or H1N1 pandemic influenza.
The research team also identified drugs that are currently on the market for different diseases that they claim block the entry of Covid-19 into human cells by increasing cellular cholesterol. In particular, they found three drugs currently on the market were more than 100-fold more effective in stopping viral entry in human lung cells:
The other five drugs that were tested called PIK-111, Compound 19, SAR 405, Autophinib, ALLN -- are used in research but are not yet branded and used in clinical trials for existing diseases.
Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus.
Their findings offer insight into novel therapies that may be effective in treating Covid-19 and reveal the underlying molecular targets of those therapies.
The bioengineers in New York were working on other projects with gene-editing technology from CRISPR but quickly pivoted to studying the coronavirus when it swept through the metropolitan area last March. "Seeing the tragic impact of Covid-19 here in New York and across the world, we felt that we could use the high-throughput CRISPR gene editing tools that we have applied to other diseases to understand what are the key human genes required by the SARS-CoV-2 virus," said Dr. Sanjana.
Dr. Neville Sanjana and his team at the New York Genome Center used CRISPR to identify the genes that can protect human cells against Covid-19.
New York Genome Center
As he explained, "current treatments for SARS-CoV-2 infection currently go after the virus itself, but this study offers a better understanding of how host genes influence viral entry and will enable new avenues for therapeutic discovery."
Previously, Dr. Sanjana has applied genome-wide CRISPR screens to identify the genetic drivers of diverse diseases, including drug resistance in melanoma, immunotherapy failure, lung cancer metastasis, innate immunity, inborn metabolic disorders and muscular dystrophy.
"The hope is that the data from this study which pinpoints required genes for SARS-CoV-2 infection could in the future work be combined with human genome sequencing data to identify individuals that might be either more susceptible or more resistant to COVID-19," Dr. Sanjana said.
The New York team is not the first to use CRISPR gene editing techniques to fight Covid-19. Other bioengineering groups at MIT and Stanford have been using CRISPR to develop ways to fight the SARS-CoV-2 and develop diagnostic tools for Covid-19.
The potential for using CRISPR to eliminate viruses has already generated some enthusiasm in the research community. Last year, for example, Excision BioTherapeuticslicenseda technology from Temple University that uses CRISPR, combined with antiretroviral therapy, to eliminate HIV, the virus that causes AIDS.
Global Botulinum Toxin Market: Snapshot
Botulinum toxin, known to the mankind as one of the most poisonous biological substances, is a neurotoxin produced by theClostridium botulinum bacteria.Clostridium botulinum, the gram-positive, anaerobic, spore-forming bacteria commonly found in water, soil, on plants, and the intestinal tracts of animals can be elaborated into eight exotoxins, all interfering with the process of neural transmission and causing muscle paralysis.
Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1196
From the earliest recorded uses of the toxin for the management ofstrabismus in humans to being approved for the treatment of a number of spasticity-related conditions, it has now started witnessing demand across nearly all important sub-specialties of the medicine sector. It was approved by the FDA in 2002 for the cosmetic application of decreasing glabeller forehead frown lines temporarily.
Ever since, botulinum toxins continue to play a key role in the management of a wide range of medical conditions, especially hemifacial spasm, focal dystonias and strabismus, several spastic movement disorders, hyperhidrosis, hypersalivation, headaches, and certain chronic diseases that only partially respond to medical treatments. The set of potential new indications treatable by botulinum toxins is expanding at a rapid pace.
Cosmetological applications, one of the most popular and profitable applications of botulinum toxins, include correction of creases, fine lines, and wrinkles over the face, neck, chin, and chest.Dermatological applicationsof the toxin, including hyperhidrosis, are also gaining increased popularity, chiefly as botulinum toxin injections are often well tolerated and lead to few side effects.
Global Botulinum Toxin Market: Overview
The international botulinum toxin (BNT) market is gigantically advantaged by the soaring number of applications for different purposes. A recent study has revealed that BNT can be used for benefitting patients with shoulder disorders such as those who undergo rotator cuff surgery. BNT in the form of onabotulinum toxin A (OnabotA) is licensed in several countries such as Korea to help with neurogenic detrusor overactivity (NDO) induced urinary incontinence attributable to multiple sclerosis or spinal cord injury.
The world BNT market could be segregated as per two key classifications, i.e. product type and end use. Maintaining a promising share in the global market, botulinum toxin type A (BNTA) is envisioned to be a faster growing product with applications in both aesthetic and therapeutic fronts.
The report on the global BNT market has been compiled after taking comprehensive efforts to gather vital insights for procuring future growth prospects, opportunities to rise against the odds, and data related to the current and future competitive scenario.
Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1196<ype=S
Global Botulinum Toxin Market: Trends and Opportunities
The aesthetic classification by type of end use is prognosticated to make a positive difference in the overall BNT market with a record share registered in 2015. BNT finds application in the treatment of glabellar lines, crows feet, and frown lines. As a result, it has received a significant demand in terms of primary cosmetic application for controlling aging signs and enhancing facial appearance.
Since BNT is a neurotoxin, the lackluster in the adoption of neurotoxins could raise questions on the demand in the global BNT market. The market growth could be further hindered with substandard reimbursement coverage on few products and extortionate treatment procedures. Moreover, shortness of breath and allergic reactions are some of the side effects witnessed on the part of neurotoxins.
However, a substantial number of BNT applications is expected to birth in the near future on account of large investments in research and development projects. The demand for BNT is anticipated to augment even more with the increase in demand for non-invasive and minimally invasive treatments. Vendors can also keep their hopes alive during any turmoil in the market with the escalation of geriatric population.
The therapeutic use of BNT is predicted to see a constant rise owing to the growing application of botulinum toxin B (BNTB) in the treatment of cervical dystonia and Xeomin and Dysport products for hyperhidrosis and blepharospasm.
Global Botulinum Toxin Market: Regional Outlook
Asia Pacific is analyzed to possess the potential to rise as a reliable geographical segment to bet the bottom dollar on. The demand in the Asia Pacific BNT market is envisaged to aggravate as players ride on the growing aged population and their need for anti-aging products. Besides augmenting disposable income, vendors in the Asia Pacific region could heavily benefit from the hot social awareness about commercial anti-aging products in countries such as Japan, China, and India.
Having won the crown of dominant growth in 2015, North America is expected to raise the growth bar once again on the back of the elevating BNT demand for improving external appearances and other aesthetic reasons.
Global Botulinum Toxin Market: Companies Mentioned
Considering their influence in the world BNT market on the basis of commercial availability and brand identity, companies such as Merz Pharma GmbH and Co. KgaA, Ipsen Group, Allergan, Inc., US Worldmeds, LLC, and Medytox, Inc. are predicted to top the list of best global players. These players are foreseen to take advantage of the colossal adoption of BNT on account of tangible benefits such as speedy healing of wounds, shorter stay in the hospital, and small incision.
To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1196
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.